Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Thiazolidinedione (TZD) drugs used in the treatment of type 2 diabetes mellitus (T2DM) have proven effective in improving insulin sensitivity, hyperglycemia, and lipid metabolism. Though well tolerated by some patients, their mechanism of action as ligands of peroxisome proliferator-activated receptors (PPARs) results in the activation of several pathways in addition to those responsible for glycemic control and lipid homeostasis. These pathways, which include those related to inflammation, bone formation, and cell proliferation, may lead to adverse health outcomes. As treatment with TZDs has been associated with adverse hepatic, cardiovascular, osteological, and carcinogenic events in some studies, the role of TZDs in the treatment of T2DM continues to be debated. At the same time, new therapeutic roles for TZDs are being investigated, with new forms and isoforms currently in the pre-clinical phase for use in the prevention and treatment of some cancers, inflammatory diseases, and other conditions. The aims of this review are to provide an overview of the mechanism(s) of action of TZDs, a review of their safety for use in the treatment of T2DM, and a perspective on their current and future therapeutic roles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., & Spiegelman, B. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117936 · Cited by 3,543 · cited 1×
“…the production and action of the inflammatory cytokine tumor necrosis factor alpha (TNFa) (Yang and Lai 2010; Carta et al. 2011a), which is overexpressed in the adipose tissue of both obese mice and humans (Hotamisligil et al. 1993, 1995; Kern et al. 1995; Zhang et al. 2007; Aoyama et al. 2009).”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“The use of TZDs in the treatment of NASH has been explored in numerous clinical studies (e.g. NeuschwanderTetri et al. 2003; Promrat et al. 2004; Belfort et al. 2006; Aithal et al. 2008; Idilman et al. 2008; Ratziu et al. 2008; Sanyal et al. 2010), with differing results.”
BackgroundInfluentialInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 5×
“The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Inzucchi et al. 2015) recommend a treatment sequence that begins with metformin monotherapy (which is well-established and generally well-tolerated by patients), followed by the addition of one or two oral antihyperg…”
BackgroundInfluentialGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085 · cited 1×
“PPARc is predominantly expressed in white adipose tissue in both rodents and humans (Chawala et al. 1994; Tontonoz et al. 1994a, 1994b, 1995a; Hauner 2002; Evans et al. 2004; Sharma and Staels 2007; Tontonoz and Spiegelman 2008; Yau et al. 2013).”
Background
Cited by
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism
Ding, K., Liu, C., Li, L., Yang, M., Jiang, N., Luo, S., & Sun, L. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002533 · Cited by 396
Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus
Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080806 · Cited by 302
Treatment strategies against diabetes: Success so far and challenges ahead.
Khursheed, R., Singh, S. K., Wadhwa, S., Kapoor, B., Gulati, M., Kumar, R., Ramanunny, A. K., Awasthi, A., & Dua, K. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172625 · Cited by 239
Adherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
Metadata
- Authors
- Davidson, M. A., Mattison, D. R., Azoulay, L., & Krewski, D.
- Venue
- Critical Reviews in Toxicology
- Publisher
- Informa UK Limited
- Published
- 2017-08-17
- Volume
- 48
- Issue
- 1
- Pages
- 52-108
- ISSN
- 0045-6446 (ISSN-L)
- 1040-8444
- 1547-6898
- OpenAlex
- W2747369409
- Cited by
- 112
- References
- 73
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. https://app.cochat.ai/papers/10.1080/10408444.2017.1351420
- The paper
- Davidson, M. A., Mattison, D. R., Azoulay, L., & Krewski, D. (2018). Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Critical Reviews in Toxicology. https://doi.org/10.1080/10408444.2017.1351420
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.